Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...

Johnson & Johnson (J&J) MedTech has reported a 4.8% growth in global sales in 2024, though it expects its 2025 outlook to ...

Johnson & Johnson (NYSE:JNJ) traded flat in the premarket on Wednesday after the pharma giant exceeded Street forecasts for Q4 2024, mainly due to its Innovative Medicine unit, while its MedTech ...

Johnson & Johnson reported higher-than-expected fourth-quarter revenues, driven by strong cancer drug sales, amidst its ...

Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...

The Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter offers electrophysiologists the ability to switch between radiofrequency and pulsed field energy in a single, fully integrated catheter CE Mark ...

named Johnson & Johnson MedTech. The consumer side of J&J’s business – which includes brands such as BandAid, Listerine, and its well-known baby shampoo – was announced earlier this year to be ...